NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) Earnings Turn To Profitability Challenges Premium P/E Narrative
Alnylam Pharmaceuticals (ALNY) opened 2026 on the back of a strong finish to last year, with Q4 2025 revenue of US$1.1b and basic EPS of US$1.41 supported by net income of US$186.4m as the company reported its latest numbers. Over the past few quarters, revenue has moved from US$593.2m in Q4 2024 to US$594.2m in Q1 2025, then to US$773.7m in Q2 2025 and US$1.25b in Q3 2025. Basic EPS shifted from a loss of US$0.65 in Q4 2024 to US$1.91 in Q3 2025 and US$1.41 in Q4 2025, reflecting a clear...